Update on Genes Associated with Arrhythmogenic Cardiomyopathy by Vallverdú-Prats, Marta et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Update on Genes Associated with 
Arrhythmogenic Cardiomyopathy
Marta Vallverdú-Prats, Mireia Alcalde,  
Georgia Sarquella-Brugada, Sergi Cesar, Elena Arbelo, 
Josep Brugada, Ramon Brugada and Oscar Campuzano
Abstract
Arrhythmogenic cardiomyopathy is a rare genetic entity characterized by 
progressive fibro-fatty replacement of myocardium leading to malignant arrhyth-
mias, syncope, and sudden cardiac death. Mostly it affects the right ventricle, but 
cases have also been described with biventricular and even isolated left ventricular 
involvement. The disease affects mainly young males and arrhythmias are usually 
induced by exercise. Arrhythmogenic cardiomyopathy has a genetic origin and is 
basically caused by deleterious alterations in genes encoding desmosomal proteins, 
especially plakophilin-2. To date, more than 400 rare genetic alterations have been 
identified in 18 genes, mainly with autosomal dominant inheritance, but some 
recessive forms have also been reported (Naxos disease and Carvajal syndrome). 
A comprehensive genetic analysis identifies a rare variant as potential cause of the 
disease in around 60% of patients, suggesting the existence of unknown genes as 
well as other genome alterations not yet discovered. Genetic interpretation classifies 
some of these rare variants as ambiguous, playing an uncertain role in arrhyth-
mogenic cardiomyopathy. This makes a proper translation of genetic data into 
clinical practice difficult. Moreover, incomplete penetrance and variable pheno-
typic expression makes it difficult to arrive at the correct diagnosis. In the present 
chapter, we focus on recent advances in the knowledge regarding the genetic basis 
of arrhythmogenic cardiomyopathy.
Keywords: sudden cardiac death, Arrhythmogenic cardiomyopathy, arrhythmias, 
genetics, desmosome
1. Introduction
Arrhythmogenic cardiomyopathy (ACM), (Online Mendelian Inheritance in 
Man -OMIM- 107970) is a rare (prevalence 1:2500–5000) inheritable structural 
heart disease first described by Fontaine et al in 1978 [1]. ACM is characterized by 
progressive replacement of myocardium by fibro-fatty infiltrates, predominantly 
of the right ventricle (RV) [2], but biventricular forms have also been reported 
in nearly 50% of cases [3, 4]. Moreover, isolated forms affecting only the left 
ventricle have been reported in 15% of cases [5, 6]. The name of this disease has 
been changed over the last years as the knowledge of it has been increased. First, it 
was called arrhythmogenic right ventricular dysplasia (ARVD), but some studies 
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revealed that patients had normal hearts at birth and the disease was progressive 
and genetically determined [4]. For this reason, from that moment on, it was called 
arrhythmogenic right ventricular cardiomyopathy (ARVC). However, when it was 
obvious that this disease not only affects the RV but that it also can affect the LV or 
even both ventricles, it was necessary to modify its name to ACM. The heart tissue 
affected in ACM patients shows localized/diffuse atrophy with progressive fibro-
fatty infiltration. These structural alterations are assessed by echocardiography, 
cardiac magnetic resonance, angiography, and biopsy of the myocardial wall, if 
necessary. Structural alterations in the myocardium are responsible for electri-
cal abnormalities, with or without impaired mechanical function, subsequent 
ventricular arrhythmias, syncope and even sudden cardiac death (SCD) [7, 8]. 
Unfortunately, SCD is often the first symptom of the disease, usually during exer-
cise in young males (less than 35-year-old). Despite both genders being affected, 
males are the main affected population (the ratio of men to women is 3:1) [9].
ACM is a cardiac disease with a clearly genetic implication, and pathogenic 
alterations in genes encoding desmosomal proteins are the main cause of the 
disease. In recent years, continuous advances in the genetic and molecular basis of 
ACM are occurring despite some pathophysiological mechanisms involved in ACM 
being not yet completely understood [10]. For example, it has been shown that 
myocardial inflammation is a common trait in ACM patients, but it is not clear if 
it is a primary phenomenon or reactive to ACM pathology [4, 11, 12]. The fibrosis 
mechanism is another characteristic hallmark poorly understood so far. It has been 
described a complex network of interactions between cytokines, growth factors, 
and hormones that promote cardiac fibrosis [12, 13]. One thing that seems certain 
is that canonical and non-canonical TGFβ signaling pathway are both involved in 
the induction of myocardial fibrosis in ACM [12]. The origin of adipocytes in the 
myocardium of ACM patients is not yet resolved today. Thus, it is not clear if the 
signals for adipogenesis are autonomous to desmosome-expressing cells (intracellu-
lar signal) or non-autonomous from desmosome-expressing cells to adipogenic cell 
(paracrine signal) [12]. However, several signaling pathways have been described 
that are involved in the adipogenic phenotype of ACM such as WNT, Hippo–Yes-
associated protein (YAP), peroxisome proliferator-activated receptor-γ (PPARγ) 
and microRNA (miRNA) signaling [12].
Currently, clinical diagnosis is based on the presence of a series of diagnostic 
items (major and minor) called Task Force criteria. It was firstly proposed in 1994 
[14], but it was revised in 2010 to improve diagnostic sensitivity maintaining its 
specificity and included genetics as a diagnostic item [15]. Nowadays it takes into 
account structural assessment (echocardiography, magnetic resonance, RV angiog-
raphy), histological (endomyocardial biopsy), electrocardiographic (12-lead ECG 
and Signal-Averaged ECG, Holter monitoring, exercise testing, electrophysiologi-
cal study), and familial factors (genetic study according to the Rhythm Society/
European Heart Rhythm Association Consensus Statement) [16]. Recently, it 
has been proposed “The Padua Criteria”, a new diagnostic criteria based on 2010 
TFC multi-parametric approach to include biventricular and arrhythmogenic left 
ventricular cardiomyopathy (ALVC) involvement [4, 17]. However, it has to be 
validated by future clinical studies in large cohorts of ACM patients. The diagnosis 
of ACM is confirmed if 2 major, 1 major and 2 minor, or 4 minor criteria from dif-
ferent categories are present. A borderline diagnosis is considered with 1 major and 
1 minor or 3 minor criterions from different categories and a possible diagnosis with 
only 1 major or 2 minor criterions. The disease can be classified into four phases:
• The early “silent phase” that can manifest as SCD because arrhythmias occur 
without structural abnormalities;
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• The “overt electrical disorder” in which RV arrhythmias are associated with 
structural abnormalities;
• The “phase of right ventricular failure” with extension of the fibro-fatty 
 substitution that leads to RV dysfunction; and,
• The phase of “biventricular failure” which is often indistinguishable from 
dilated cardiomyopathy (DCM).
The diagnostic tools are evolving together with the knowledge of the disease 
because detecting ACM at an early stage is crucial for the patient. All the treat-
ment approaches are focused on preventing life-threatening arrhythmias, delay 
the course of the heart failure, and relieve symptoms [12]. The different options 
include pharmacological treatment, the placement of an implantable cardioverter- 
defibrillator (ICD), radiofrequency ablation, and even heart transplantation in 
severe cases at high risk of death. To date, ICD is the only proven lifesaving therapy; 
other treatment options may reduce the arrhythmic burden and alleviate symptoms, 
without evident impact on prevention of SCD [18]. There are some studies that 
have demonstrated the efficacy of ICD therapy in the prevention of SCD in patients 
affected by ACM [19–22]. However, it is associated with a significant morbidity due 
to device-related complications and inappropriate ICD interventions [1]. Decisions 
about the placement of an ICD are based on an estimated patient risk of SCD that is 
determined by several parameters including electrical instability, proband status, 
extent of structural disease, cardiac syncope, male gender, exercise practice, and 
deleterious genetic alterations. Unfortunately, there are no conclusive data con-
cerning risk stratification or the best approach in patients with ACM, so treatment 
should be personalized [23].
2. Genetic basis
ACM can be caused by deleterious alterations located in genes encoding mainly 
desmosomal proteins but also proteins implicated in electric signal transmission. 
A comprehensive genetic analysis of all genes reported so far identify at least one 
rare variant as a potential cause of ACM in around 60% of the patients [24]. Genetic 
testing allows cascade screening of relatives identifying other genetic carriers in 
the family, which may be at risk of developing the disease and suffer SCD [25]. 
Predominantly, ACM follows an autosomal dominant pattern of inheritance, with 
incomplete and age-related penetrance [26] as well as polymorphic phenotypic 
expression [9, 27]. Autosomal recessive forms have also been reported although in a 
reduced number of cases (Naxos disease and Carvajal syndrome) [28–30]. In recent 
years, compound and/or digenic variants have been identified associated with ACM 
[31, 32]. In addition, alterations in number of copies (Copy Number Variation, 
CNV) were also associated with ACM [33]. Despite these recent advances, around 
35–50% of ACM patients remain without an identified disease-associated variant 
[12]. For this reason, the interpretation of rare variants found in ACM patients has 
to be extremely careful. The “American College of Medical Genetics and Genomics 
(ACMG) standards and guidelines” structured a standard terminology for clas-
sifying sequence variants using available evidence weighted according to a system 
developed through expert opinion, work-group consensus, and community input 
[34]. This classification of the variants is composed of 5 terms: “pathogenic”, “likely 
pathogenic”, “uncertain significance”, “likely benign”, and “benign” and the clas-
sification depends on several different criteria: the variant frequency in population 
Cardiomyopathy - Disease of the Heart Muscle
4
database, computational (in silico) predictive programs, biological factors (levels 
of expression in the tissue, function of the gene,…), localization of the variant in 
conserved regions or hotspots, type of mutation, functional studies and segrega-
tion analyses. It is important to remark that a large part of the rare genetic variants 
identified as potentially disease-causing remains of inconclusive significance after 
a comprehensive genetic interpretation. It is crucial to clarify their clinical role 
whether definitive risk stratification can be based on genetics. Even if a conclusive 
pathogenic variation associated with ACM is identified, it does not indicate that 
the patient is going to be affected because of the variable expressivity and incom-
plete penetrance [4]. This represents an additional challenge to perform a genetic 
interpretation of rare variants. Moreover, it is known that genes associated with 
ACM have nearly 50% of genetic variation rate [35]. Therefore, clinical translation 
should be done carefully after a comprehensive personalized interpretation of all 
data obtained. A group of experts should discuss all data concerning each family, 
performing an exhaustive interpretation and translation into clinical practice help-
ing to adopt personalized measures to reduce risk of lethal events.
In the human myocardium, three different structures are involved in cell-to-cell 
adhesion: desmosomes, adherens junctions (fascia adherens), and gap junctions. 
The majority of ACM patients present alterations in genes encoding desmosomal 
proteins. Currently, more than 1000 rare genetic variants have been identified in 18 
genes, but only around 400 rare genetic alterations have been classified as definitely 
pathogenic [36]. All other rare variants remain with an ambiguous role and fur-
ther data is needed to conclude if they play a decisive role in ACM. Table 1 shows 
information related to the genetic role and ventricular involvement of the ACM 
causal genes (plakophilin-2 -PKP2-, desmocollin-2 -DSC2-, desmoglein-2 -DSG2-, 
desmoplakin -DSP-, plakoglobin -JUP-, desmin -DES-, transforming growth factor 
beta-3 -TGFβ3-, transmembrane protein 43 -TMEM43-, lamin A/C -LMNA-, titin 
-TTN-, phospholamban -PLN-, αT-catenin -CTNNA3-, voltage-gated sodium 
channel -SCN5A-, Cadherin 2 -CDH2-, Filamin C -FLNC-, Ryanodine Receptor 
2 -RYR2-, RNA-Binding Motif Protein 20 -RBM20-, Tight Junction Protein ZO-1 
-TJP1-) [4, 11]. Figure 1 presents the intracellular localization of proteins codified 
by ACM-associated genes and their prevalence in causing the disease.
2.1 Desmosomal genes
Desmosomes are classified as a calcium-dependent anchoring junction that 
tethers cells together through its extracellular contacts and internally links to the 
intermediate filament (IF) cytoskeleton [37]. This cell union provide structural 
resilience that allows heart tissue to resist mechanical stress. Moreover, it has been 
described that desmosomal proteins have a role in the regulation of transcrip-
tion of genes involved in adipogenesis and apoptosis, and play a major role in 
myocardial electrical conduction through regulation of gap junctions and calcium 
homeostasis [4]. Deleterious alterations are mainly located in genes encoding 
desmosomal proteins that are responsible for around 60% of all ACM cases [4, 17]. 
Concretely, the main gene associated with ACM is PKP2, being responsible for 
approximately 35–40% of cases [35, 38, 39]. Pathogenic variants in PKP2 are found 
in around 75% of genotype-positive ACM cases in American cohorts, and nearly 
60% of genotype-positive index cases in European cohorts [4, 40]. In general, rare 
variants in genes encoding desmosomal proteins are more associated with right 
ventricular involvement. However, rare deleterious alterations in DSP are often 
associated with left ventricular involvement, and DSG2 and PKP2 with biventricu-
lar ACM, although the latter is observed in all gene groups at later stages of disease 
 progression [4, 9].
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2.1.1 Plakophilin-2
The most prevalent form of ACM is caused by rare pathogenic alterations in 
the PKP2 gene (ENSG00000057294), which encode plakophilin-2 protein (PKP2, 
ENSP00000070846). It is an essential armadillo repeat protein located in the outer 
dense plaque of cardiac desmosomes that interacts with multiple other cell adhesion 
proteins [41]. To date, more than 300 rare genetic variants potentially pathogenic 
have been identified in PKP2 [42]. Most of the ACM-linked pathogenic variants in the 
PKP2 gene have an autosomal dominant pattern of inheritance, even though recessive 
form was also described in 2006 [30]. Lately, calcium handling dysregulation caused 
by disruption of PKP2 has been described [43]. It seems that PKP2 is necessary to main-
tain transcription of genes that control intracellular calcium cycling. This could be the 
cause of life-threatening arrhythmias even in the absence of structural disease in those 
patients that present alterations in PKP2, which are the majority of ACM patients.







PKP2 plakophilin-2 19–46 AD/AR RV, BIV
DSP desmoplakin 1–16 AD/AR LV, BIV
DSG2 desmoglein-2 2.5–10 AD/AR RV, LV, BIV
DSC2 desmocollin-2 1–8 AD RV, BIV
JUP plakoglobin Rare AD/AR RV, BIV
Adherens junction
CTNNA3 αT-catenin Rare AD RV, BIV
CDH2 cadherin 2 Rare AD RV, BIV
TJP1 tight Junction Protein ZO-1 Rare AD ?
Cytoskeletal structure
LMNA lamin A/C Rare AD LV, BIV
DES desmin Rare AD LV, BIV
FLNC filamin C Rare AD LV, BIV
TMEM43 transmembrane protein 43 Rare AD RV, BIV
TTN titin Rare AD RV, LV, BIV
Ion transport
SCN5A voltage-gated sodium channel Rare AD LV, BIV
RYR2 ryanodine Receptor 2 Rare AD ?
PLN phospholamban Rare AD LV, BIV
Cytokine




RBM20 RNA-Binding Motif Protein 20 Rare AD LV
*Taken from Austin et al. (2019) [51].
**Taken from Patel et al. (2020) [4].
? = Not conclusive association with ACM. AD = autosomal dominant; AR = autosomal recessive; BIV = biventricular 
disease; LV = left ventricle; RV = right ventricle.
Table 1. 
Genes associated with ACM.
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2.1.2 Desmoplakin
Desmoplakin is the most abundant protein of the desmosomes, encoded by the 
DSP gene (ENSG00000096696). Desmoplakin has two isoforms produced by alterna-
tive splicing: the longest desmoplakin I isoform (ENSP00000369129) and the shorter 
desmoplakin II (ENSP00000396591). Desmoplakin isoform I has been reported to be a 
force constituent of desmosomes and the major isoform present in cardiac tissue, even 
though expression of isoform II (DSPII) occurs in different heart compartments [44]. 
Nowadays, almost 250 rare variations in the DSP gene have been linked to ACM [42], 
mainly with autosomal dominant pattern of inheritance. The DSP gene was also impli-
cated in Carvajal syndrome, an autosomal recessive cardiocutaneous form of ACM that 
was described as a variant of Naxos disease (see below, plakoglobin section) [45].
2.1.3 Desmocollin-2 and Desmoglein-2
The desmosomal cadherins proteins, such as desmocollin and desmoglein are the 
major constituents of the desmosomal plaque. The DSG2 gene (ENSG0000046604) 
encodes Desmoglein-2 protein (DSG2, ENSP00000261590) that has four extracellu-
lar cadherin domains and a transmembrane domain. Currently, more than 150 rare 
variants have been associated to ACM [42]. Despite the fact that most of the identi-
fied DSG2 mutations have a dominant pattern of inheritance, a recessive pattern has 
been also suggested in ACM patients [46]. The DSC2 gene (ENSG00000134755) 
encodes the desmocollin protein type 2 (DSC2, ENSP00000280904), the most 
widely distributed form of desmocollin proteins [47]. It is a type I integral mem-
brane glycoprotein with four conserved extracellular subdomains, variable extra-
cellular anchor domain, a single transmembrane domain, an intracellular anchor 
domain, and additional cytoplasmatic subdomains. It participates in calcium-
dependent cell adhesion, regulation of tissue morphogenesis and intracellular 
signaling processes [48]. To date, nearly 120 genetic alterations have been identified 
in DSC2 associated with ACM following an autosomal pattern of inheritance [42].
Figure 1. 
Schematic representation of the intracellular localization of proteins codified by genes associated with ACM. 
Created with BioRender.com
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2.1.4 Plakoglobin
The plakoglobin protein (PG, ENSP00000311113) is codified by the JUP gene 
(ENSG00000173801). PG is a major protein component of cell adhesion junctions, 
and the only constituent common to submembranous plaques of both desmosomes 
and adherens junctions. It plays a crucial role in linking the desmosomal cadherins 
to the cytoskeleton via desmoplakin. The first genetic alteration associated with 
ACM was an homozygous deletion in the JUP gene, with an autosomal recessive pat-
tern of inheritance [28]. In later years, it was referred to as “Naxos disease” [49]. To 
date, more than 30 rare genetic variants have been identified in JUP [42], including 
homozygous variants [50].
2.2 Non-desmosomal genes
This group includes genes encoding proteins of cytoskeletal architecture, cal-
cium handling, sodium transport, and cytokine signaling among others. All of them 
have a diverse range of biological functions, but a pathogenic alterations in them 
can converge into similar phenotypes [51]. Genetic defects in non-desmosomal 
genes are thought to be more frequently associated with involvement of the left 
ventricle compared with rare variants in desmosomal genes that, in general, are 
more often associated with RV involvement [4]. There are several rare deleterious 
alterations in non-desmosomal genes that cause ACM that are also involved in 
other cardiac diseases such as DCM, Brugada syndrome (BrS), Long QT syndrome 
(LQTS) or Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). 
Thereby, in some cases, there is an overlap of symptoms that makes it challeng-
ing to determine the correct diagnosis. For this reason, it is necessary to perform 
more studies of genotype–phenotype correlation to increase the reliability of the 
diagnosis.
2.2.1 Desmin
The DES gene (ENSG00000175084) encodes the protein desmin (DES, 
ENSP00000363071) that is the main intermediate filament in mature skeletal and 
heart muscle cells. It forms a scaffold around the Z-disc and links whole contractile 
structure with subsarcolemmal cytoskeleton, intercalated disc, nucleus, and other 
components of the cytoplasm. Currently, less than 10 rare variants in this gene have 
been associated with ACM [42, 52, 53].
2.2.2 Transforming growth factor, beta-3
The TGFβ3 gene (ENSG00000119699) encodes the transforming growth factor, 
beta-3 protein (TGFβ3, ENSP00000238682), a cytokine that stimulates fibrosis and 
modulates cell adhesion and expression of desmosomal genes [54]. To date, there 
are only 4 rare alterations located in TGFβ3 as potential causes of ACM.
2.2.3 Transmembrane protein 43
The TMEM43 gene (ENSG00000170876) encodes the transmembrane protein 
43 (TMEM43, ENSP00000303992). It has an important role in maintaining nuclear 
envelope structure by organizing protein complexes at the inner nuclear membrane. 
Moreover, it has been suggested to have a role in an adipogenic pathway [55]. To 
date, around 15 ACM associated rare variants in TMEM43 has been identified [42], 
Cardiomyopathy - Disease of the Heart Muscle
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one of them (p.S358L) exhibits an aggressive phenotype presenting with a fully 
penetrant, biventricular ACM with LV predominance and a high predilection for 
SCD in males [4, 55–57].
2.2.4 Lamin A/C
The LMNA gene (ENSG00000160789) encodes lamin A (ENSP00000357283) 
and lamin C (ENSP00000357284), by alternative splicing. Both of them belong 
to the family of type V intermediate filaments that take part in the constitution 
of the nuclear lamina, a complex of proteins below the inner part of the nuclear 
membrane [58]. Genetic alterations in LMNA are associated with an heterogeneous 
group of disorders commonly named “laminopathies” [59], including cardiac disor-
ders with DCM as the main disease. In 2012, the first association between this gene 
and ACM was reported [60]. To date, nearly 25 rare variants have been described in 
LMNA associated with ACM [42].
2.2.5 Titin
The TTN gene (ENSG00000155657) encodes the titin protein (TTN, 
ENSP00000343764) that is a giantic and the third most abundant protein in the 
muscle after actin and myosin. It is an essential component of the sarcomere linking 
myosin and the Z-disc, providing structural support, flexibility, and stability [4]. 
This gene has been associated with cardiac diseases, mainly DCM. In 2011 the first 
variant associated with ACM was reported [61]. To date, more than 20 rare variants 
have been associated with ACM [42]. Most of these variants remain as potentially 
pathogenic, with doubtful role due to lack of conclusive genotype–phenotype studies.
2.2.6 Phospholamban
The PLN gene (ENSG00000198523) encodes the protein phospholamban 
(PLN, ENSP00000350132), a small phosphoprotein closely associated with the 
cardiac sarcoplasmic reticulum. It is a regulator of the sarcoplasmic reticulum Ca2+ 
(SERCA2a) pump in cardiac muscle and therefore important for maintaining Ca2+ 
homeostasis [62]. Consequently, the PLN protein is one of the major determinants 
of cardiac contractility and relaxation [63]. To date, only one rare pathogenic vari-
ant associated with ACM has been identified in this gene [42, 64].
2.2.7 Alpha T-catenin
The CTNNA3 gene (ENSG00000183230) encodes the protein αT-catenin 
(CTNNA3, ENSP00000389714). Alpha T-catenin protein is located within the area 
composite of intercalated discs of cardiomyocytes. It is a key element for dynamic 
maintenance of tissue morphogenesis by integrating in the cadherin–catenin com-
plex. In 2013, genetic variants of potentially pathogenic significance were identified 
in two unrelated patients suffering from ACM [42, 65]. Moreover, it has been shown 
that CTNNA3 knockout mice exhibit a progressive cardiomyopathy with increased 
incidence of ventricular arrhythmias after acute ischemia [4, 66]. To date, no other 
rare variants associated with ACM have been identified in this gene.
2.2.8 Voltage-gated sodium channel
The SCN5A gene (ENSG00000183873) encodes for the cardiac sodium channel, 
voltage-gated, type V, alpha subunit (SCN5A, ENSP00000410257). This gene is 
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mainly associated with BrS and LQTS but it was also reported in patients diagnosed 
with ACM [67]. Recently, a study suggested that almost 2% of ACM patients harbor 
rare SCN5A variants [68]. In total, for the moment, no more than 10 SCN5A rare 
variants associated with ACM have been described.
2.2.9 Cadherin 2
The CDH2 gene (ENSG00000170558) encodes the protein cadherin type 2 
(CDH2, ENSP00000269141) that is a large transmembrane adherens junction 
protein that connects actin filaments in neighboring cardiomyocyte sarcomeres [4, 
69]. It is a member of the cadherin superfamily and provides strength and stability 
to cardiac tissue and calcium-ion-dependent adhesion among other functions. In 
2017 data were published regarding the firsts cadherin variants associated with 
ACM in this gene [70, 71]. To date, only 3 rare variants have been associated with 
ACM [42, 72].
2.2.10 Filamin C
The FLNC gene (ENSG00000128591) encodes for the protein filamin C (FLNC, 
ENSP00000327145) that is an actin cross-linking protein associated with Z-discs 
found only in striated muscle, important for structural cell stability and membrane-
triggered signal transduction [4, 51]. Pathogenic alterations in FLNC have been 
linked to skeletal myopathies as well as DCM and restrictive cardiomyopathies and 
possibly hypertrophic cardiomyopathy. Recently, this gene, particularly truncating 
variants, have been associated with ventricular arrhythmias and a high SCD risk 
[73, 74]. To date, it has been described that nearly 30 FLNC rare variants are associ-
ated with ACM [42].
2.2.11 Ryanodine receptor 2
The RYR2 gene (ENSG00000198626) encodes for the protein Ryanodine 
Receptor 2 (RYR2, ENSP00000355533) that is a sarcoplasmic reticulum calcium 
release channel that mediates the release of Ca2+ from the sarcoplasmic reticu-
lum into the cytoplasm which generates calcium transients to trigger sarcomere 
contraction. The majority of RYR2 deleterious alterations are associated with 
CPVT, but there are some studies that have been shown that rare variants in 
RYR2 can also cause ACM [75, 76]. For the moment, there are nearly 20 rare 
variants associated with ACM [42]. However, it is necessary to continue inves-
tigating the relationship between RYR2 and ACM to clarify the overlapping in 
diagnosis. There has even been described a case where the causal genetic altera-
tion could not be identified, but the patient presented with phenotypes of both 
disorders [77].
2.2.12 RNA-binding motif protein 20
The RBM20 gene (ENSG00000203867) encodes for the protein RNA-Binding 
Motif Protein 20 (RBM20, ENSP00000358532) that acts as a regulator of mRNA 
splicing of a subset of genes involved in cardiac development (sarcomeric, calcium 
regulation and ion regulation genes). There have been identified several rare 
alterations in RBM20 implicated in DCM and ACM and that causes severe arrhyth-
mia and SCD [78–81]. Therefore, pathogenic alterations in RMB20 are associated 
with a high propensity for malignant arrhythmias usually with minor structural 
 abnormalities [4, 80].
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2.2.13 Tight junction protein ZO-1
The TJP1 gene (ENSG00000104067) encodes for the protein tight junction 
protein Zona Occludens-1 (TJP ZO-1, ENSP00000281537), a multi-functional 
scaffolding protein that localizes to the intercalated discs of cardiomyocytes and 
interacts with proteins of gap junctions and area composita including connexin43, 
N-cadherin, αT-catenin, and actin [4]. Recently, it has been identified that 4 rare 
variants in ACM patients could be deleterious according to in silico tools predictions 
[42, 82]. Case–control studies provided evidence for enrichment with TJP1 variants 
in ACM patients compared with controls, supporting the causality role of TJP1 in 
ACM. Further evidence from larger cohorts for the role of TJP1 as a disease causing 
in ACM is still needed [4, 82].
3. Conclusion
Arrhythmogenic cardiomyopathy is an inherited rare cardiac disease character-
ized by progressive replacement of myocardium by fibrofatty tissue, leading to 
ventricular arrhythmias and sudden cardiac death. Structural abnormalities mainly 
occur in the right ventricle, but it is well recognized that also sole left ventricular 
involvement and even biventricular substitution is common, particularly in 
advanced stages of the disease. Several molecular mechanisms are involved in 
the phenotype of ACM such as myocardial inflammation and signaling pathways 
that cause fibrosis and adipogenesis. Today, most of these mechanisms are not 
completely understood. Task Force Criteria for the diagnosis of arrhythmogenic 
cardiomyopathy include several clinical tests and also genetic data. Despite progres-
sive improvement in diagnosis, it is difficult to obtain conclusive risk stratifica-
tion in families suffering from arrhythmogenic cardiomyopathy. Hundreds of 
rare alterations are reported in mainly genes encoding desmosomal proteins, but 
there are also other causal genes with several functions within the cardiac tissue. 
A comprehensive genetic analysis may identify the potential genetic cause of the 
disease in nearly 60% of cases. Genetic testing is especially useful in families with 
at least one affected member that carries a potential deleterious alteration because 
it allows early identification and adoption of therapeutic measures among relatives 
at risk of malignant arrhythmias. Currently, one of main challenges is the genetic 
interpretation and clinical translation of amount of genetic data generated by new 
genetic technologies.
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